跳至主要内容
临床试验/NCT01370187
NCT01370187已完成不适用

Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing in Infants 3 to 12 Months of Age in Bandar Abbas Children' Hospital

Hormozgan University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 146 人开始时间: 2010年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
146
试验地点
1
主要终点
Respiratory Distress Severity Score (RDSS)

研究概览

简要总结

The aim of the current study is to evaluate the effect of Montelukast in treatment of acute bronchiolitis and postbronchiolitis viral induced wheezing of infants 3 to 12 months of age in Bandar Abbas Children' hospital.

详细描述

All the patients will be evaluated at the baseline, during hospitalization (daily) and at 2 months and 6 months after starting the intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
3 Months 至 12 Months(Child)
性别
All
接受健康志愿者

入选标准

  • infant in 3-12 months of age with first episode of wheezing or bronchiolitis
  • written informed consent by parents

排除标准

  • Previous wheezing episode or confirmed asthma or bronchiolitis
  • recent bronchodilator use
  • immune deficient
  • immunosuppressive drug use
  • croup or pneumonia diagnosis
  • loss of follow up

研究组 & 干预措施

Montelukast

Experimental

4mg Montelukast daily for 2 months

干预措施: Montelukast (Drug)

结局指标

主要结局

Respiratory Distress Severity Score (RDSS)

时间窗: participants will be followed for the duration of hospital stay, an expected average of 3 days

RDSS is measured by wheezing (0, 1, 2)+ Cough (0, 1, 2)+Retraction (0, 1,2)+Respiratory rate(0,1,2)+ Oxygen saturation(0,1,2) scores

次要结局

  • average number of cough daily= as expressed parents during visits(6 months)
  • Wheezing severity in the physical examination by physician(6 Months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验